History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention
- 19 August 2016
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 36 (8), 880-892
- https://doi.org/10.1002/phar.1790
Abstract
Invasive meningococcal disease caused by Neisseria meningitidis presents a significant public health concern. Meningococcal disease is rare but potentially fatal within 24 hours of onset of illness, and survivors may experience permanent sequelae. This review presents the epidemiology, incidence, and outbreak data for invasive meningococcal disease in the United States since 1970, and it highlights recent changes in vaccine recommendations to prevent meningococcal disease. Relevant publications were obtained by database searches for articles published between January 1970 and July 2015. The incidence of meningococcal disease has decreased in the United States since 1970, but serogroup B meningococcal disease is responsible for an increasing proportion of disease burden in young adults. Recent serogroup B outbreaks on college campuses warrant broader age-based recommendations for meningococcal group B vaccines, similar to the currently recommended quadrivalent vaccine that protects against serogroups A, C, W, and Y. After the recent approval of two serogroup B vaccines, the Advisory Committee on Immunization Practices first updated its recommendations for routine meningococcal vaccination to cover at-risk populations, including those at risk during serogroup B outbreaks, and later it issued a recommendation for those aged 16-23 years. Meningococcal disease outbreaks remain challenging to predict, making the optimal disease management strategy one of prevention through vaccination rather than containment. How the epidemiology of serogroup B disease and prevention of outbreaks will be affected by the new category B recommendation for serogroup B vaccines remains to be seen.Keywords
Funding Information
- Pfizer
This publication has 35 references indexed in Scilit:
- Epidemiology of Infant Meningococcal Disease in the United States, 2006-2012PEDIATRICS, 2015
- Changes in the Population Structure of InvasiveNeisseria meningitidisin the United States After Quadrivalent Meningococcal Conjugate Vaccine LicensureThe Journal of Infectious Diseases, 2015
- The changing epidemiology of meningococcal disease in North America 1945–2010Human Vaccines & Immunotherapeutics, 2013
- Meningococcal disease: Clinical presentation and sequelaeVaccine, 2012
- The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal diseaseVaccine, 2011
- Meningococcal carriage by age: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Epidemiology and Meningococcal Serogroup Distribution in the United StatesClinical Pediatrics, 2010
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal DiseaseClinical Infectious Diseases, 2010
- Increased Case‐Fatality Rate Associated with Outbreaks ofNeisseria meningitidisInfection, Compared with Sporadic Meningococcal Disease, in the United States, 1994–2002Clinical Infectious Diseases, 2006
- Clinical recognition of meningococcal disease in children and adolescentsThe Lancet, 2006